Marcus Droege
Nova Southeastern University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marcus Droege.
Value in Health | 2009
Richard A. Hansen; Joel F. Farley; Marcus Droege; Matthew L. Maciejewski
Objectives: Healthcare costs for adherent patients were compared with costs for nonadherent patients in a cohort with diabetes mellitus taking metformin, sulfonylureas, or pioglitazone. Methods: Using both the commercial and Medicare supplemental MEDSTAT MarketScan® research databases, a retrospective cohort study identified 108,592 continuously insured patients 18 to 90 years of age with diabetes mellitus (ICD-9-CM 250.xx) using metformin, sulfonylureas, or pioglitazone monotherapy during 2003. Adherence was calculated in 2004 and 2005 using a medication possession ratio, and dichotomized at ≥80% to indicate adherence. Total healthcare costs included insurer payments and patient cost-sharing from medical (inpatient, outpatient) and prescription drug claims. Diabetes-specific costs included pharmacy claims for any diabetes drug and medical claims containing a primary diagnosis of diabetes or a diabetes complication. Multivariate analysis was conducted to adjust for potential confounders. Results: During the initial year of follow-up, the proportion of patients adherent to treatment were 57%, 61%, and 59% for metformin, sulfonylureas, anad pioglitazone, respectively. Annual unadjusted total healthcare costs were consistently lower for adherent patients than for non-adherent patients (
Pharmacy Practice (internet) | 2006
Marcus Droege; Wallace A. Marsh; Goar Alvarez; Tracy S. Hunter
1,470 less for metformin users,
Pharmacy Education | 2004
Marcus Droege
3,734 less for sulfonylurea users, and
The American Journal of Pharmaceutical Education | 2008
Kathy Fuller; Maria Maniscalco-Feichtl; Marcus Droege
3,477 for pioglitazone users). In the multivariate models, total healthcare costs and diabetes specific healthcare costs respectively were
Research in Social & Administrative Pharmacy | 2008
Sean T. Leonard; Marcus Droege
846 (95% CI
The American Journal of Pharmaceutical Education | 2007
J. Chris Bradberry; Marcus Droege; R. Lee Evans; Joseph Guglielmo; David A. Knapp; Katherine K. Knapp; Susan M. Meyer; Therese I. Poirier; Cecilia M. Plaza
747 to
Research in Social & Administrative Pharmacy | 2005
Richard A. Hansen; Marcus Droege
945) and
The American Journal of Pharmaceutical Education | 2005
Marcus Droege; Michelle T. Assa-Eley
55 (95% CI
Research in Social & Administrative Pharmacy | 2006
Lawrence M. Brown; Jon C. Schommer; Dave Mott; Caroline A. Gaither; William R. Doucette; Dave P. Zgarrick; Marcus Droege
33 to
The Journal of pharmacy technology | 2007
Marcus Droege; Maria Maniscalco; Karen L. Daniel; H. John Baldwin
77) per year lower for adherent patients compared to nonadherent patients. The adjusted annual adherence-related cost difference was